Amadeus Capital Partners and Cambridge Innovation Capital invest

Tuesday 14 April

Cambridge-based Congenica, a spinout from The Wellcome Trust Sanger Institute, has raised a further £2.2m with the completion of a series A round of financing by Amadeus Capital Partners’ early stage funds and the company’s initial investor Cambridge Innovation Capital.

Congenica was launched in 2014 by six world leading geneticists and bio-informaticians. It has developed a proprietary platform to screen whole genome sequence data to identify novel genetic mutations and to highlight those associated with inherited or acquired genetic disorders.

Collectively, rare genetic disease affects some 6% of people, three quarters of whom are children. The UK alone has 3.5 million people affected – the EU 30 million. 80% of rare diseases are thought to have a genetic basis, but a small fraction are diagnosed molecularly, a process that would provide much faster and more accurate diagnoses and prognoses.

Congenica’s core technology Sapientia^TM has already proved capable of accurately diagnosing children with previously undiagnosed problems. This information will improve disease diagnosis and, especially in the case of children with rare genetic disorders, to determine the best therapies and support for the patient and their family.

In addition, the technology also allows the efficient analysis of complex genomic data to facilitate drug discovery. The extreme phenotypes associated with rare genetic diseases provide useful insights into the origins of more widespread diseases such as diabetes.

This funding will be used to further develop Congenica’s technology to become the gold standard clinical genomic analytics platform, capable of processing big data sets of human DNA sequence to generate a definitive molecular diagnosis. This will improve interpretation of genetic disease for treatment and assist in new drug discovery.

In March 2015, it was announced that Congenica had been awarded £2m by Genomics England in its SBRI Phase Two assessment of Enabling Technologies for Genomics Sequence Data Analysis and Interpretation. This award followed confirmation that Congenica had been selected by Genomics England as one of the winners in the genome annotation competition.

Congenica CEO, Dr Tom Weaver, whose career includes helping to build a number of start-ups including Hexagen and Geneservice, says:

“Amadeus Capital Partners has a strong reputation for identifying disruptive technologies and the investment is an excellent endorsement of the potential of our Sapientia technology. Coupled with the continued support of Cambridge Innovation Capital, we have an excellent investor base and have now achieved £5m in funding and grants and which will help us take the technology into the clinic and accelerate our growth.”

Amadeus Partner, Hermann Hauser who joins Congenica’s Board of Directors, says: “We are convinced that accurate gene sequencing and related diagnoses are the way forward for a number of inherited debilitating conditions and that this will build a better world for all our children. With Solexa (now acquired by Illumina), Cambridge put itself firmly on the map for these technologies and we have every confidence that Congenica will become a similarly important company.”

Peter Keen, CEO of Cambridge Innovation Capital and Board member of Congenica adds: “This increased investment will expedite Congenica’s aim of taking the ground-breaking research work of the Wellcome Trust Sanger Institute to the clinic for the wider benefit of patients”.

Advisers on the transaction were Taylor Wessing and Taylor Vinters.

ENDS

Notes for editors follow

Media enquiries for Amadeus Capital Partners
Chantal Ligertwood
+44 (0)7976 229 210
chantal@ligertwood.net

Media enquiries for Congenica and Cambridge Innovation Capital
Rachel Holdsworth/Anna Masefield, Holdsworth Associates PR
Tel: +44 1954 202789 or email: anna.masefield@holdsworth-associates.co.uk

About Congenica
www.congenica.com
Congenica, is a world leading developer of genome-based discovery and diagnostic technologies.

Congenica is a spin-out from The Wellcome Trust Sanger Institute. It was founded by six world leading geneticists and bioinformaticians in genomic sequencing, including Dr Richard Durbin who led the international 1000 Genomes Project and the UK10K Genome Project and Dr Matthew Hurles Senior Group Leader at the Wellcome Trust Sanger Institute and a leader in the Deciphering Developmental Disorders (DDD) project.

Congenica has developed Sapientia^TM technology platform, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report. It is based on pioneering research from the Wellcome Trust Sanger Institute, NHS clinicians and regional genetic testing laboratories.

This underlying technology has been validated by leading independent institutes and clinicians, including Genomics England Ltd.

Recent relevant papers include: Genetic diagnosis of developmental disorders in the DDD study. ‘Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data’, The Lancet, published online Dec 17, pp.1-10, Letter: ‘Large-scale discovery of novel genetic causes of developmental disorders’, Nature (2014).

About Amadeus Capital Partners
amadeus.wedevelopdigital.co.uk
Amadeus has an 18-year history of successful technology investing. Since its inception, the firm has backed over 90 companies from 10 funds totalling over $1bn in cumulative commitments. Amadeus has a presence in the UK, Sweden, US, India and South Africa and the team has deep experience of technology. Major businesses built by Amadeus include Optos (LSE:OPTS), Solexa, acquired by Illumina Inc. (ILMN), and CSR (LSE:CSR).

About Cambridge Innovation Capital
www.cambridgeinnovationcapital.com
Cambridge Innovation Capital (“CIC”) was launched with initial funding from long-term institutional and strategic investors including Invesco Perpetual, Lansdowne Partners and the University of Cambridge Endowment Fund. We invest in high-growth life science and technology companies arising from the University of Cambridge and the wider Cambridge Cluster. With our close ties to the University, active angel groups and the entrepreneurial community, our mission is to be one of the leading venture capital investors in the vibrant Cambridge Cluster. Where needed, our investment strategy backed by our permanent capital structure, allows us to provide long-term financial support to our portfolio companies.

About the Wellcome Trust Sanger Institute
http://www.sanger.ac.uk/
The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.